<?xml version='1.0' encoding='utf-8'?>
<document id="19299526"><sentence text="In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions."><entity charOffset="62-75" id="DDI-PubMed.19299526.s1.e0" text="thiabendazole" /></sentence><sentence text="Thiabendazole (TBZ) and its major metabolite 5-hydroxythiabendazole (5OH-TBZ) were screened for potential time-dependent inhibition (TDI) against CYP1A2"><entity charOffset="0-13" id="DDI-PubMed.19299526.s2.e0" text="Thiabendazole" /><entity charOffset="15-18" id="DDI-PubMed.19299526.s2.e1" text="TBZ" /><entity charOffset="45-67" id="DDI-PubMed.19299526.s2.e2" text="5-hydroxythiabendazole" /><entity charOffset="69-76" id="DDI-PubMed.19299526.s2.e3" text="5OH-TBZ" /><entity charOffset="73-79" id="DDI-PubMed.19299526.s2.e4" text="TBZ" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e0" e2="DDI-PubMed.19299526.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e0" e2="DDI-PubMed.19299526.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e0" e2="DDI-PubMed.19299526.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e0" e2="DDI-PubMed.19299526.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e0" e2="DDI-PubMed.19299526.s2.e4" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e1" e2="DDI-PubMed.19299526.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e1" e2="DDI-PubMed.19299526.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e1" e2="DDI-PubMed.19299526.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e1" e2="DDI-PubMed.19299526.s2.e4" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e2" e2="DDI-PubMed.19299526.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e2" e2="DDI-PubMed.19299526.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e2" e2="DDI-PubMed.19299526.s2.e4" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e3" e2="DDI-PubMed.19299526.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19299526.s2.e3" e2="DDI-PubMed.19299526.s2.e4" /></sentence><sentence text=" Screen assays were carried out in the absence and presence of NADPH"><entity charOffset="63-68" id="DDI-PubMed.19299526.s3.e0" text="NADPH" /></sentence><sentence text=" TDI was observed with both compounds, with k(inact) and K(I) values of 0" /><sentence text="08 and 0" /><sentence text="02 min(-1) and 1" /><sentence text="4 and 63" /><sentence text="3 microM for TBZ and 5OH-TBZ, respectively"><entity charOffset="21-28" id="DDI-PubMed.19299526.s8.e0" text="5OH-TBZ" /><entity charOffset="13-19" id="DDI-PubMed.19299526.s8.e1" text="TBZ" /><entity charOffset="25-31" id="DDI-PubMed.19299526.s8.e2" text="TBZ" /><pair ddi="false" e1="DDI-PubMed.19299526.s8.e1" e2="DDI-PubMed.19299526.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19299526.s8.e1" e2="DDI-PubMed.19299526.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19299526.s8.e1" e2="DDI-PubMed.19299526.s8.e2" /><pair ddi="false" e1="DDI-PubMed.19299526.s8.e0" e2="DDI-PubMed.19299526.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19299526.s8.e0" e2="DDI-PubMed.19299526.s8.e2" /></sentence><sentence text=" Enzyme inactivation was time-, concentration-, and NADPH-dependent"><entity charOffset="52-54" id="DDI-PubMed.19299526.s9.e0" text="NADPH" /></sentence><sentence text=" Inactivation by TBZ was irreversible by dialysis and oxidation by potassium ferricyanide, and there was no protection by glutathione"><entity charOffset="67-89" id="DDI-PubMed.19299526.s10.e0" text="potassium ferricyanide" /><entity charOffset="122-133" id="DDI-PubMed.19299526.s10.e1" text="glutathione" /><entity charOffset="17-27" id="DDI-PubMed.19299526.s10.e2" text="TBZ" /><pair ddi="false" e1="DDI-PubMed.19299526.s10.e2" e2="DDI-PubMed.19299526.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19299526.s10.e2" e2="DDI-PubMed.19299526.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19299526.s10.e2" e2="DDI-PubMed.19299526.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19299526.s10.e0" e2="DDI-PubMed.19299526.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19299526.s10.e0" e2="DDI-PubMed.19299526.s10.e1" /></sentence><sentence text=" 5OH-TBZ was a weak TDI of CYP1A2, and enzyme activity was recovered by dialysis"><entity charOffset="1-8" id="DDI-PubMed.19299526.s11.e0" text="5OH-TBZ" /><entity charOffset="5-11" id="DDI-PubMed.19299526.s11.e1" text="TBZ" /><pair ddi="false" e1="DDI-PubMed.19299526.s11.e0" e2="DDI-PubMed.19299526.s11.e0" /><pair ddi="false" e1="DDI-PubMed.19299526.s11.e0" e2="DDI-PubMed.19299526.s11.e1" /></sentence><sentence text=" IC(50) determination of TBZ and 5OH-TBZ showed both compounds to be potent inhibitors, with IC(50) values of 0"><entity charOffset="25-28" id="DDI-PubMed.19299526.s12.e0" text="TBZ" /><entity charOffset="33-40" id="DDI-PubMed.19299526.s12.e1" text="5OH-TBZ" /><entity charOffset="37-43" id="DDI-PubMed.19299526.s12.e2" text="TBZ" /><pair ddi="false" e1="DDI-PubMed.19299526.s12.e0" e2="DDI-PubMed.19299526.s12.e0" /><pair ddi="false" e1="DDI-PubMed.19299526.s12.e0" e2="DDI-PubMed.19299526.s12.e1" /><pair ddi="false" e1="DDI-PubMed.19299526.s12.e0" e2="DDI-PubMed.19299526.s12.e2" /><pair ddi="false" e1="DDI-PubMed.19299526.s12.e1" e2="DDI-PubMed.19299526.s12.e1" /><pair ddi="false" e1="DDI-PubMed.19299526.s12.e1" e2="DDI-PubMed.19299526.s12.e2" /></sentence><sentence text="83 and 13" /><sentence text="05 microM, respectively" /><sentence text=" IC(50) shift studies also demonstrated that TBZ was a TDI of CYP1A2"><entity charOffset="45-47" id="DDI-PubMed.19299526.s15.e0" text="TBZ" /></sentence><sentence text=" In silico methods identified the thiazole group as a TDI fragment and predicted it as the site of metabolism"><entity charOffset="34-42" id="DDI-PubMed.19299526.s16.e0" text="thiazole" /></sentence><sentence text=" The observation pointed to epoxidation of the thiazole and the benzyl rings of TBZ as possible routes of metabolism and mechanisms of TDI"><entity charOffset="47-55" id="DDI-PubMed.19299526.s17.e0" text="thiazole" /><entity charOffset="64-70" id="DDI-PubMed.19299526.s17.e1" text="benzyl" /><entity charOffset="80-85" id="DDI-PubMed.19299526.s17.e2" text="TBZ" /><pair ddi="false" e1="DDI-PubMed.19299526.s17.e0" e2="DDI-PubMed.19299526.s17.e0" /><pair ddi="false" e1="DDI-PubMed.19299526.s17.e0" e2="DDI-PubMed.19299526.s17.e1" /><pair ddi="false" e1="DDI-PubMed.19299526.s17.e0" e2="DDI-PubMed.19299526.s17.e2" /><pair ddi="false" e1="DDI-PubMed.19299526.s17.e1" e2="DDI-PubMed.19299526.s17.e1" /><pair ddi="false" e1="DDI-PubMed.19299526.s17.e1" e2="DDI-PubMed.19299526.s17.e2" /></sentence><sentence text=" Drug-drug interaction (DDI) simulation studies using SimCyp showed good predictions for competitive inhibition" /><sentence text=" However, predictions for mechanism-based inhibition (MBI)-based DDI were not in agreement with clinical observations" /><sentence text=" There was no TBZ accumulation upon chronic administration of the drug"><entity charOffset="14-16" id="DDI-PubMed.19299526.s20.e0" text="TBZ" /></sentence><sentence text=" The in vitro MBI findings might therefore not be capturing the in vivo situation in which the proposed bioactivation route is minor" /><sentence text=" This might be the case for TBZ in which, in vivo, UDP glucuronosyltransferases and sulfanotransferase metabolize and eliminate the 5OH-TBZ"><entity charOffset="28-30" id="DDI-PubMed.19299526.s22.e0" text="TBZ" /><entity charOffset="136-138" id="DDI-PubMed.19299526.s22.e1" text="TBZ" /><pair ddi="false" e1="DDI-PubMed.19299526.s22.e0" e2="DDI-PubMed.19299526.s22.e0" /><pair ddi="false" e1="DDI-PubMed.19299526.s22.e0" e2="DDI-PubMed.19299526.s22.e1" /></sentence><sentence text="" /></document>